For research use only, not for therapeutic use.
GRL0617（Cat No.:I018166）is a selective inhibitor of the protein phosphatase 2A (PP2A) and has emerged as a promising tool in cancer research. By specifically targeting PP2A, GRL0617 disrupts its regulatory functions, leading to enhanced phosphorylation of key oncogenic pathways that promote tumor growth. This compound has demonstrated potential in preclinical studies for its ability to sensitize cancer cells to conventional therapies and overcome drug resistance. Additionally, GRL0617 is being explored for its implications in neurodegenerative diseases, positioning it as a versatile candidate for therapeutic development in various conditions.
| Catalog Number | I018166 |
| CAS Number | 1093070-16-6 |
| Molecular Formula | C₂₀H₂₀N₂O |
| Purity | ≥95% |
| Storage | 2–8 °C |
| IUPAC Name | 5-amino-2-methyl-N-[(1R)-1-naphthalen-1-ylethyl]benzamide |
| InChI | InChI=1S/C20H20N2O/c1-13-10-11-16(21)12-19(13)20(23)22-14(2)17-9-5-7-15-6-3-4-8-18(15)17/h3-12,14H,21H2,1-2H3,(H,22,23)/t14-/m1/s1 |
| InChIKey | UVERBUNNCOKGNZ-CQSZACIVSA-N |
| SMILES | CC1=C(C=C(C=C1)N)C(=O)N[C@H](C)C2=CC=CC3=CC=CC=C32 |
| Reference | [1]. Ratia K, et al. A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication. Proc Natl Acad Sci U S A. 2008 Oct 21;105(42):16119-24. |
